Overview

A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

Status:
Completed
Trial end date:
2018-10-11
Target enrollment:
0
Participant gender:
Male
Summary
Investigate the safety, tolerability and pharmacokinetics of BAY1093884 after Intravenous (IV) and subcutaneous (SC) administration of increasing single doses and SC administration of multiple doses.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bayer
Criteria
Inclusion Criteria:

- Males with severe congenital Hemophilia A or B defined as <1% FVIII or Factor IX (FIX)
concentration by measurement at the time of screening or from reliable prior
documentation

- For subjects in Cohorts I-IV, I-SC1 and I-SC2; If history of inhibitors is evident,
inhibitor titer of ≥5 Bethesda Units (BU) at screening or prior to screening at any
time from medical records.

- Age: 18 to 65 years of age at screening

- Body mass index (BMI): 18 to 29.9 kg/m²

Exclusion Criteria:

- Subjects with known bleeding disorders (such as von Willebrand factor [vWF]
deficiency, FXI deficiency, platelet disorders, or known acquired or inherited
thrombophilia etc.) other than congenital Hemophilia A or B with or without inhibitors

- History of angina pectoris or treatment for angina pectoris

- History of coronary and/or peripheral atherosclerotic disease, congestive heart
failure, disseminated intravascular coagulopathy, or stage 2 hypertension defined as
systolic blood pressure (SBP) ≥160 mmHg or diastolic blood pressure (DBP) ≥100 mmHg
even if controlled

- History of thrombophlebitis, venous / arterial thromboembolic diseases (particularly
deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction,
cerebrovascular accident, ischemic heart disease, transient ischemic attack)

- Known or suspected hypersensitivity of the immune system, history of anaphylactic
reaction, known (clinically relevant) allergies, non-allergic drug reactions, or
multiple drug allergies